Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186875 · ClinicalTrials.gov registry record · Phase 2
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
A Phase 2 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT00186875 is a Phase 2 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 47 participants.
The verdict
NCT00186875, a Phase 2 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
The main purpose of this study is to find out how well participants with relapsed or refractory ALL respond to treatment with an etoposide- and teniposide-based induction chemotherapy regimen and what the side effects are. Primary Objectives: * To estimate the response rate for patients with refractory or relapsed ALL. * To estimate the survival rate of patients with refractory or relapsed ALL treated with risk-directed therapy.
Interventions
- DRUG Etoposide, cytarabine, vincristine, dexamethasone
- DRUG methotrexate, teniposide, PEG-asparaginase
- DRUG mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine
- DRUG L-asparaginase, erwinia asparaginase
- PROCEDURE chemotherapy, intrathecal chemotherapy, steroid therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2003-11 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00186875
The ClinicalTrials.gov registry entry for NCT00186875 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Etoposide, cytarabine, vincristine, dexamethasone is the first listed.
NCT00186875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00186875 about?
NCT00186875 is a clinical study titled "Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia". The main purpose of this study is to find out how well participants with relapsed or refractory ALL respond to treatment with an etoposide- and teniposide-based induction chemotherapy regimen and what the side effects are. Primary Objectives: * To estimate the response rate for patients with refra...
What is the current status of trial NCT00186875?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2003-11. Estimated completion is 2016-08.
What interventions are being tested in trial NCT00186875?
The interventions under investigation include: Etoposide, cytarabine, vincristine, dexamethasone (DRUG), methotrexate, teniposide, PEG-asparaginase (DRUG), mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine (DRUG), L-asparaginase, erwinia asparaginase (DRUG), chemotherapy, intrathecal chemotherapy, steroid therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00186875?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.